Strategic Objective
The final objective of our group is to contribute to pharmacogenetics and precision medicine. We try to identify genetic biomarkers that could be used to predict who patients will have better response, benefit and outcome and lesser toxicity to specific drugs.
Planned Research Projects
- Genetic biomarkers of toxicity in oncological immunotherapy
- Genetic biomarkers of efficacy in oncological immunotherapy
- Worldwide genetic variability in polymorphisms associated with COVID severity
Transfer of Results
- Contributions in national and international congresses
- Publications in JCR journals
Training and education programme
- Students of medicine, nursery, etc, will be able to join to the group as PhD students
Dissemination
- Publications in JCR journals and national and international congresses
- Guides for physicians
Internationalization
The team will call for European programs when specific programs related to our research will be opened. Gender Equality Quality Program: Gender equality is achieved in our group because women and men have the same conditions and opportunities to belong and to work with us.
Research Lines
Pharmacogenetics and cancer
- Pharmacogenetics in breast cancer
- Pharmacogenetics in colorectal cancer
- Pharmacogenetics and immunotherapy
Genetic variability of human populations